New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:38 EDTENDP, BDSIEndo Health trial results more meaningful to partner, says Cantor
Cantor views the positive top-line results from the trial of BEMA buprenorphine reported by Endo Health (ENDP) as more meaningful to its partner, BioDelivery Sciences (BDSI), than to Endo. Cantor see the product opportunity for this drug to be modest and maintains its Sell rating and $43 price target on Endo Health.
News For ENDP;BDSI From The Last 14 Days
Check below for free stories on ENDP;BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
August 14, 2014
07:46 EDTENDPEndo valuation attractive, says Goldman
Subscribe for More Information
August 12, 2014
07:11 EDTBDSIBioDelivery Sciences and Endo Pharmaceuticals report on BEMA Buprenorphine NDA
Subscribe for More Information
August 8, 2014
09:00 EDTBDSI, ENDPBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.
August 7, 2014
17:29 EDTBDSIBioDelivery Sciences sees U.S. launch of Bunavail in late Q3
Subscribe for More Information
17:27 EDTBDSIBioDelivery Sciences reports Q2 EPS (14c), consensus (13c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use